Abstract
TRAIL causes apoptosis in numerous types of tumor cells. However, the mechanisms regulating TRAIL-induced apoptosis remain to be elucidated. We have investigated the role of PKC in regulating TRAIL-induced mitochondrial events and apoptosis in the Jurkat T cell line. We found a caspase-dependent decline in mitochondrial membrane potential and translocation of cytochrome c from mitochondria into the cytosol in response to TRAIL. Both these events were prevented by PKC activation. Moreover, PKC activation considerably reduced the activation of caspases, PARP cleavage and apoptosis when induced upon TRAIL treatment. MAPK activation was involved in the mechanism of PKC-mediated inhibition of TRAIL-induced cytochrome c release from mitochondria. Furthermore, inhibition of the MAPK pathway partially reversed the PKC-mediated inhibition of TRAIL-induced apoptosis. Besides, PKC activation may also inhibit the TRAIL-induced apoptosis through a MAPK-independent mechanism. Altogether, these results indicate a negative role of PKC in the regulation of apoptotic signals generated upon TRAIL receptor activation.
Similar content being viewed by others
Introduction
Apoptosis is a cell death process that is required for integrity and homeostasis of multicellular organisms and is also important in pathological situations.1,2 The past decade has witnessed an enormous progress in our knowledge of the pathway for the execution of apoptotic cell death. Several members of the tumor necrosis factor (TNF) family have so far been reported to play an important role in the induction of apoptosis.3 TRAIL (APO-2 ligand), a recently discovered member of the TNF family, is a type II transmembrane protein which provokes apoptosis mainly in tumor cells.4 TRAIL also functions as an apoptosis inducer in activation-induced cell death, immune privilege, T cell-mediated cytotoxicity and autoimmunity.5,6,7,8,9 TRAIL mRNA is constitutively present in many tissues unlike the restricted expression of CD95L, another pro-apoptotic member of the TNF family.10,11 TRAIL has four specific receptors, namely TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4, of which TRAIL-R1, -R2 and -R4 are type I transmembrane proteins whereas -R3 is a glycosylphosphatidyl inositol linked protein. The mRNAs of TRAIL-R1, -R2 and -R4 are as frequently expressed as that of TRAIL whereas that of TRAIL-R3 is rather restricted. TRAIL-R1 and -R2 are ‘death receptors’, with cytoplasmic death domains that trigger apoptotic cell death, whereas TRAIL-R3 and TRAIL-R4 are ‘decoy receptors’ which are unable to transduce death signals and could inhibit TRAIL-induced apoptosis.12,13,14,15,16,17,18,19,20
Although rapid advances in our understanding of the biology of CD95-mediated cell death have unveiled exciting new perspectives in this area of research, progress in understanding TRAIL-induced apoptosis has been rather modest thus far, and often contradictory results have been reported.12,13,14,15,21,22,23,24,25 However, more recent data have demonstrated that TRAIL receptors recruit the adapter protein FADD for caspase-8 activation.26,27,28 Apical caspase processing is followed by activation of BID, processing of caspase-9, -3 and -7, cleavage of the nuclear enzyme poly(ADP-ribose)polymerase (PARP) and apoptotic cell death.29,30,31
There is emerging evidence for the importance of signals from mitochondria during the effector phase of apoptotic cell death.32 Results of several investigations have suggested that apoptosis-inducing agents like CD95L and TNF-α can trigger the uncoupling of electron transport from ATP production, with the resultant decrease of membrane potential (ψm),33 which can be attributed to the opening of a mitochondrial permeability transition (PT) pore.32 Through this PT pore, cytochrome c is released into the cytosol34,35 and together with Apaf-1 and procaspase-9 induce the activation of caspase-9, leading to activation of caspase-3 and downstream apoptotic events.36,37,38 However, other investigations have revealed that mitochondrial cytochrome c release could also occur independently of mitochondrial PT.39 The role of mitochondria in death receptor-mediated apoptosis has largely been examined in the case of CD95-mediated apoptosis,40 although more recent research has also addressed the involvement of mitochondria-related events in TRAIL-induced apoptosis.41,42
Recent results have provided substantial evidences that serine/threonine PKC upon activation by phorbol ester could inhibit apoptosis triggered by different inducers,43,44,45 including CD95 ligation.46,47,48,49 It is known that PKC activates the MAPK pathway.50,51,52 Nevertheless, several independent lines of evidence indicate that PKC prevents CD95-mediated apoptosis by both MAPK pathway-dependent53,54,55 and -independent55 mechanisms. However, the regulation of TRAIL-induced apoptosis seems to be more complex than that induced by CD95L.41,42
The findings outlined above prompted us to study the role of PKC, if any, in regulating TRAIL-induced apoptosis. We hereby report that treatment of human Jurkat T cells with a PKC activator markedly interferes with caspase activation, mitochondrial events and apoptosis induced by TRAIL. In this work, we have also addressed the question as to the role played by the MAPK pathway in mediating this PKC-induced survival mechanism.
Results
Protein kinase C activation prevents TRAIL-induced apoptosis
Activation of apoptotic TRAIL receptors by TRAIL has important implications for the selective elimination of tumor cells and the use of TRAIL as a therapeutic agent is a matter of growing interest.56 On the other hand, TRAIL could also play a role in activation-induced cell death of T lymphocytes.7 In this respect, it has been previously shown that Jurkat T lymphocytes are very sensitive to TRAIL-induced apoptosis.6,26,28 Jurkat cells mainly express mRNA (Figure 3c) and protein22,26,28 for TRAIL-R2, though we also detected a significant amount of mRNA for TRAIL-R1 (Figure 3c) and -R4 (results not shown).
Activation of the serine/threonine PKC elicits survival signals in many different systems, including CD95-induced apoptosis.43,44,45,46,47,48,49 Since the regulation of TRAIL-mediated cell death appears to be more complex than that induced by CD95L,41,42 we were interested on investigating whether PKC activation could modulate TRAIL-mediated apoptosis. Results shown in Figure 1a indicate that in Jurkat cells, TRAIL-induced chromatin condensation was abrogated in presence of the PKC activator PDBu. In order to quantify this effect, we determined by FACS analysis the effect of PKC activation on the induction of hypodiploid apoptotic cells in TRAIL-treated Jurkat cells. As shown in Figure 1b (left panel), in cultures of Jurkat cells treated with TRAIL for 15 h there was a marked induction of apoptosis as compared to the control cultures. In contrast, a considerable reduction in the percentage of apoptotic cells in the cultures was observed when Jurkat cells were incubated with TRAIL in the presence of PKC activator (Figure 1b, left panel). This inhibition was similar to that observed in the presence of a non-cytotoxic dose (50 μM) of Z-VAD-fmk (Figure 1b, right panel), a broad spectrum caspase inhibitor.57 Furthermore, PDBu continued to exert its apoptosis-inhibitory action till our experimental period of 48 h (Figure 1c).
One of the key biochemical events associated with apoptosis is the cleavage by caspases of the 116-113 kDa nuclear enzyme PARP within the bipartite nuclear location signal to produce two fragments of 85 and 29 kDa.58 By Western blot analysis, we determined the cleavage of PARP in Jurkat cells incubated with TRAIL for 8 h. The 85 kDa fragment of PARP cleavage was clearly visualized in TRAIL-treated cells (Figure 2a). However, PARP cleavage was significantly diminished in the presence of PKC activator in TRAIL-treated cells (Figure 2a). These results suggested that PKC was playing a negative role in apoptotic signals generated upon ligation of TRAIL receptors which lead to the activation of execution caspases.
During apoptosis, caspases are activated by cleavage of their inactive native forms. To investigate the step in TRAIL-induced apoptosis that is affected by PKC, we analyzed the processing of caspase-8, the most apical caspase activated in both CD9559,60 and TRAIL-induced apoptosis.26,27,28,31 Processing of caspase-8 upon TRAIL receptor ligation has been recently described in different cells.26,27,28,30,31 In TRAIL-treated Jurkat cells, we detected both the 55 and 53 kDa inactive pro-forms corresponding to caspase-8a and -8b as well as the 43 and 41 kDa intermediate products corresponding to cleavage of both caspase-8a and -8b between the large and small subunits (Figure 2b). This cleavage process finally results in the release of the large 18 kDa subunit and the assembly of the active caspase.61 Interestingly, when co-stimulated with PKC activator, a markedly reduced cleavage of caspase-8 was observed in TRAIL-treated Jurkat cells (Figure 2b). These results suggested that PKC activation could be blocking TRAIL-induced apoptosis at the initiator caspase-8 level. However, as caspase-8 can also be activated through a feedback loop involving mitochondria,62 we could not exclude the possibility that the inhibition of caspase-8 observed in our studies was a secondary effect of a block in a TRAIL-induced, mitochondria-regulated pathway.
PKC-mediated inhibition of TRAIL-induced apoptosis is protein synthesis-independent and is still observed after delayed addition of PDBu
Resistance of cells to death receptor-induced apoptosis has been associated with the presence of short-lived inhibitory proteins which can be removed by protein synthesis inhibitors.63,64,65 To ascertain whether PDBu-induced resistance to TRAIL-mediated apoptosis was due to the induction of such inhibitors, we examined by RT–PCR the mRNA levels of cFLIP and IAPs in Jurkat cells treated with the PKC activator. As shown in Figure 3a, Jurkat cells express a certain amount of mRNA for cFLIP and X-IAP, but these levels were not up-regulated following an 8 h treatment with PDBu. Jurkat cells did not express hIAP1 mRNA and was not induced by PDBu (not shown). Furthermore, we determined the protein synthesis requirement of PDBu-induced resistance. As protein synthesis inhibitors caused apoptosis (Figure 3b), in these experiments Jurkat cells were pre-treated with CHX and subsequently incubated for a short time (3 h instead of the usual 8 h incubation) in the absence or presence of TRAIL. Results shown in Figure 3b indicate that CHX-treated Jurkat cells were clearly more sensitive to TRAIL-mediated apoptosis than cells incubated without this protein synthesis inhibitor. However, when incubated in the presence of PDBu, CHX-treated cells were still markedly resistant to the apoptosis-inducing effect of TRAIL (Figure 3b).
To test whether down-regulation of the expression of pro-apoptotic TRAIL receptors or inhibition of TRAIL-mediated clustering of these receptors were involved in the inhibitory action of PDBu,55 we carried out two different experimental approaches. First, we measured by RT–PCR the mRNA levels of TRAILR1 and TRAILR2 in cells incubated for 8 h with PDBu. Stimulation of Jurkat cells with PDBu did not alter mRNA levels of these receptors (Figure 3c). Second, we examined the effect of a delayed addition of PDBu on TRAIL-induced apoptosis. As shown in Figure 3d, TRAIL-induced apoptosis can still be markedly inhibited by PKC activation even 2 h after the addition of TRAIL. Since assembly of the DISC and activation of initiator caspase-8 in Jurkat cells are probably maximal 1 h after the addition of TRAIL,26,28 the above results suggested that changes in receptor levels or clustering are not likely involved in the inhibitory effect of PDBu.
Caspase-dependent mitochondrial events in TRAIL-induced apoptosis and its prevention by protein kinase C activation
It has recently become evident that mitochondria is involved in CD95-mediated apoptosis in CD95 type II cells.40 Loss of mitochondrial transmembrane potential (ψm) and translocation of mitochondrial cytochrome c into the cytosol have been observed early after apoptosis induction.35 These mitochondrial changes induced by CD95 ligation in Jurkat cells are caspase-dependent.66 Recent reports have described similar findings in TRAIL-treated cells, although the role of mitochondria in TRAIL-induced apoptosis remains controversial.41,42,67 To determine whether PKC activation was affecting mitochondrial signalling in TRAIL-induced apoptosis, we have examined mitochondrial membrane potential as well as the presence of cytochrome c in the cytosol of TRAILR-stimulated cells. Similar to recently reported findings,41,42,67 we found that the number of cells with a decreased mitochondrial membrane potential markedly increased when the cells were incubated with TRAIL for 8 h (Figure 4a). The fall in membrane potential was completely prevented in presence of the caspases inhibitor Z-VAD-fmk (Figure 4a, right panel). Likewise, TRAIL induced the release of cytochrome c into the cytosol of Jurkat cells (Figure 4b, upper panels), and this effect was also inhibited by Z-VAD-fmk (Figure 4b, right panel). These results confirmed recent works41,42,67 and provided compelling evidence for the involvement of caspases upstream of mitochondrial changes induced by TRAIL. To further investigate the role of PKC activation as a protecting event of TRAIL-induced apoptosis, we studied the effect of PDBu on both TRAIL-induced loss of mitochondrial membrane potential and cytochrome c release. Results of these experiments indicated (Figure 4a, left panel) that the reduction in ψm induced by TRAIL in Jurkat cells was checked considerably in cells co-stimulated with PDBu. Similarly, when we determined the sub-cellular localization of cytochrome c in TRAIL-treated Jurkat cells, we observed that the marked translocation of cytochrome c from mitochondria into the cytosol induced by TRAIL was almost completely prevented by co-treatment with PDBu (Figure 4b, left panels). Further evidence of the inhibitory action of PKC in the mitochondria-operated pathway activated upon TRAIL receptor ligation, was obtained when we examined the activation of caspase-9. Once released from mitochondria, cytochrome c will bind to Apaf-1, an event that triggers oligomerization of Apaf-1/cytochrome c in complexes that activate procaspase-9.68 Figure 4c illustrates that TRAIL activated the processing of caspase-9 in Jurkat cells and this effect was considerably inhibited by PKC activation.
Activation of the MAPK pathway is partially required for PKC-mediated prevention of TRAIL-induced apoptosis
Activation of PKC in cells results in the stimulation of the MAPK pathway.50,51,52 The MAPK pathway plays a survival role and inhibits CD95-mediated apoptosis.53,54,55 Based on these results, we decided to evaluate the role of MAPK activation in PKC-induced prevention of TRAIL-mediated cytochrome c release and apoptosis by using PD 098059, a specific inhibitor of MEK-1 activation.69 Figure 5a shows that PKC activation prevented in a dose-dependent manner the release of cytochrome c into the cytosol. Maximal inhibition was achieved at PDBu doses between 10 and 20 ng/ml. Interestingly, TRAIL-induced release of cytochrome c from mitochondria was not prevented by PKC activation when cells were incubated in the presence of PD 098059 (Figure 5a). In the presence of the MEK1 inhibitor, the activation of the MAPK pathway by PDBu, was substantially abolished (Figure 5b). We next examined whether PD 098059 was able to prevent PKC-mediated inhibition of TRAIL-induced caspase-3 activation and apoptosis in Jurkat cells. Results shown in Figure 5c indicate that the MEK1 inhibitor only slightly reduced the PDBu-induced inhibition of TRAIL-mediated caspase-3 activation and attenuated the inhibitory effect of PKC activation on TRAIL-induced apoptosis (Figure 5d). However, prevention by PD 098059 of PKC-mediated inhibition of TRAIL-induced apoptosis was never complete, suggesting a possible existence of a MAPK-independent and PKC-dependent mechanism that may have also participated in inhibition of TRAIL receptor-mediated cell death.
Discussion
Receptors for death ligands are expressed in many tumor cells which can therefore be killed by the appropriate ligands.4 These observations offer the possibility of using death ligands as anti-tumor agents. However, in systemic anti-tumor treatments, severe toxic effects have been observed with TNF-α and CD95 ligand. TNF-α causes a lethal inflamatory response70 and CD95L produces lethal liver damage.71 In contrast, repeated systemic exposure of non-human primates to elevated doses of TRAIL does not produce significant changes in clinical parameters.56,72 These in vivo results are in agreement with data obtained in vitro indicating that TRAIL is not cytotoxic toward a variety of cultured normal cells.56 All these observations point out to a possible use of TRAIL as a new anti-tumor agent in human malignancies.72
Despite the potential of TRAIL as a useful tool in anti-cancer therapy, very little is known about the mechanisms regulating the sensitivity to TRAIL-induced apoptosis. It has been suggested that the expression of decoy receptors TRAIL-R3 and -R4, may restrain the sensitivity of cells to TRAIL.12,13,14,15,16,17,18,19,20 However, analyses of TRAIL receptor expression in a number of human tumor cell lines have indicated no correlation between TRAIL sensitivity and TRAIL-R3/R4 mRNA expression.73 Our results conclusively indicate for the first time that PKC activity could be an important regulator of apoptotic signals emerging from TRAIL receptors. Recent data have demonstrated the existence of two types of cells (I and II) in terms of the apoptosis signalling mechanism downstream of CD95 activation.40 Although mitochondrial parameters are affected in both cell types upon CD95 ligation at the cell surface, over-expression of bcl-2 only inhibits CD95-induced apoptosis in type II cells,40 indicating the existence of a mitochondria-mediated CD95-induced mechanism of apoptosis in these cells. Jurkat cells have been previously classified as CD95 type II cells.62 In this respect, we have demonstrated that the induction by TRAIL of a caspase-dependent mitochondrial apoptotic pathway is severely impaired when cells are incubated with a PKC activator. Our results therefore raise the question whether the TRAIL mediated apoptosis in Jurkat cells is essentially dependent on the observed mitochondrial changes. In this respect, it has been demonstrated that ectopic expression of bcl-2 inhibits TRAIL-induced apoptosis in certain cells.74 However, more recent work have reported that Bcl-2 overexpression does not inhibit TRAIL-induced cytochrome c release41 and apoptosis.41,42 Whether these discrepancies reflect different levels of expression of transfected Bcl-2 is not known. Our data indicate that the inhibitory action of PDBu in TRAIL-mediated apoptosis does not involve any change in the expression of TRAIL death receptors mRNA in Jurkat cells. Nevertheless, we can not completely exclude the possible loss of TRAIL apoptotic receptors at the protein level. Besides, PKC activation through phosphorylation of DISC components, may also inhibit a non-mitochondrial mechanism of apoptosis induced by TRAIL, as reported for CD95.55,75 Work in this direction is currently in progress in our laboratory. However, our data on the delayed addition of PDBu to TRAIL-treated cells indicate that a step downstream of DISC formation as well as the initiator caspase-8 activation by TRAIL is negatively regulated by PKC activation. The initiator caspase-8 activation by TRAIL is a primary event26,27,28 that may subsequently lead to BID cleavage31 and the stimulation of mitochondrial events.41,42 We are currently investigating BID cleavage and its translocation to mitochondria in TRAIL-treated cells and its possible regulation by PKC.
The signalling mechanism that results from PKC activation which inhibits the TRAIL-induced apoptosis, has been addressed in our work. As a consequence of PKC activation, p21 ras and the protein kinases c-raf, MEK1 and ERK1/2 become sequentially activated.50,51,52 Activation of the MAPK pathway prevents apoptosis and promotes cell survival.76 More recently, activation of this pathway has also been found to repress apoptosis triggered by CD95 activation.53,54,55 Our present observations indicate for the first time, that activation by PKC of the MAPK pathway plays a crucial role in the abrogation of TRAIL-induced cytochrome c release in Jurkat cells. It however remains to be resolved as to how the activation of the MAPK pathway results in the resistance to TRAIL-mediated cytochrome c release. Recent data have indicated that the expression of intracellular apoptosis inhibitors such as FLIP, a protein with homology to caspase-8 that lacks catalytic activity,77 could be responsible for resistance to TRAIL-induced apoptosis in melanoma cells.30 However, more recent results show no correlation between FLIP expression and resistance to TRAIL in these tumor cells.78 Although MAPK stimulation in Jurkat T cells with concanavalin A has recently been reported to induce FLIP,54 we however have found no changes in FLIP (L/S) or IAPs mRNA expression when Jurkat cells are treated with PDBu. These results support our data with CHX in which we show that the PDBu-mediated inhibitory action is protein synthesis-independent.
A very recent report has described that resistance of certain cells to CD95-mediated apoptosis can be reversed by the use of PD 098059.79 Literature abounds in evidences of increased MAPK activities in tumor cells.80,81 Hence it may not sound unreasonable to assume that TRAIL resistant tumors may also have a constitutively active MAPK pathway. If this assumption stands out to be valid, our results may have important clinical implications in cancer therapy since the treatment of these TRAIL-resistant tumors with inhibitors of the MAPK pathway could sensitise these cells to soluble TRAIL. However, reversal of PKC-mediated inhibition of cytochrome c release from mitochondria by PD 098059 does not completely abolish the apoptosis inhibitory effect of PKC activation. These data may indicate that a MAPK-independent mechanism downstream of cytochrome c release is also activated by PKC, which attenuates TRAIL receptor-mediated caspase-3 activation and apoptosis. In this respect, PKC-dependent activation of mitochondrial Raf-1 has been recently described to induce an anti-apoptotic effect.82 On the other hand, it has been described that cytochrome c-induced proteolytic processing of pro-caspase-9 is defective in cytosolic extracts from cells expressing active Akt,83 a molecular target of the anti-apoptotic activity of PKC in certain cells.84 These apart, an alternative explanation points out that a caspases cascade pathway independent of mitochondria42 is also blocked by PKC activation. We are currently exploring these possibilities in order to get more insight into the mechanism underlying the PKC-dependent and MAPK-independent abrogation of TRAIL-induced apoptosis.
Materials and Methods
Materials
RPMI 1640 medium and FBS were obtained from GIBCO Europe. PDBu, CHX and DAPI (4′,6′-diamidino-2-phenylindole) were purchased from Sigma (Poole, UK). Recombinant human TRAIL was obtained from Prepro Tech EC LTD (London, England). The inhibitor of MEK1 activation, PD 098059, was purchased from Calbiochem-Novabiochem GmbH (Band Soden, Germany). Mouse anti-human caspase-8 mAb was purchased from Cell Diagnostica (Münster, Germany). Rabbit polyclonal antiserum against PARP was purchased from Boehringer Mannheim (Germany). Mouse phospho-ERK1/2 mAb recognising activated ERK1/2 was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse ERK1/2 mAb was purchased from Zymed (San Francisco, CA, USA). Mouse anticytochrome c mAb was obtained from Pharmingen (San Diego, CA, USA). Mouse anti-BCL-2 mAb was from DAKO (Denmark) Mouse anti-FADD mAb was from Transduction Laboratories (Lexington, KY, USA). Rabbit polyclonal antibodies to caspase-9 p37 fragment and caspase-3 p17 subunit were obtained from New England BioLabs Inc. (Beverly, MA, USA). Monoclonal antibody to alpha-tubulin was purchased from Sigma (Poole, UK). Caspases inhibitor Z-VAD-FMK was from Enzyme System Inc. (Dublin, CA, USA). DiOC6(3) was purchased from Molecular Probes (Eugene, OR, USA).
Cell culture
Cells of the human leukemic T cell line Jurkat were maintained in culture in RPMI 1640 medium containing 10% FCS and 1 mM L-glutamine, at 37°C in a humidified 5% CO2/95% air incubator.
Determination of apoptotic cells
Analysis by flow cytometry of hypodiploid apoptotic cells was performed on a FACScan cytometer using the Cell Quest software (Becton Dickinson, Mountain View, CA, USA), after extraction of the degraded DNA from apoptotic cells following a recently described method.85 Chromatin condensation was assessed after staining of cellular DNA with DAPI by viewing the cell preparations under a Zeiss Axiophot fluorescent microscope.
Mitochondrial membrane potential
Loss of mitochondrial membrane potential was assessed with DiOC6(3) as described.86
Cytochrome c release from mitochondria
For measurements of cytochrome c release from mitochondria, cells were lysed and cytosolic fractions were separated from mitochondria as previously described.87 Cytosolic proteins (40 μg of protein) were mixed with Laemmli buffer and resolved on SDS-12% PAGE minigels. Cytochrome c was determined by Western blot analysis as described below.
Immunoblot detection of proteins
Cells (106) were washed with phosphate-buffered saline (PBS), resuspended in 20 μl sample buffer (50 mM Tris-HCl pH 6.8, 6 M urea, 6% 2-mercaptoethanol, 3% SDS, 0.003% bromophenol blue) and sonicated. Proteins were resolved on either 10% or 12% SDS-polyacrylamide minigels and transferred onto Immobilon membranes (Millipore). The blots were blocked with 5% milk powder in PBS/0.1% Tween-20 and then incubated with primary antibodies. Blots were stained with horseradish peroxidase-conjugated secondary antibodies and developed using enhanced chemiluminiscence (ECL, Amersham Life Sciences, UK) according to the manufacturer's instructions.
Reverse transcription PCR
Total RNA was isolated from cells with Trizol reagent (Life Technologies, Inc. Grand Island, NY, USA) as recommended by the supplier. cDNAs were synthesized from 2 μg of total RNA using a RT–PCR kit (Perkin Elmer, Norwalk, CT, USA) with the supplied oligo d(T) primer under conditions described by the manufacturer. PCR reactions were performed using the primers and conditions already described.5,54,88
Abbreviations
- PKC:
-
Protein kinase C
- TNF:
-
tumor necrosis factor
- TRAIL:
-
Tumor necrosis factor-related apoptosis-inducing ligand
- MAPK:
-
mitogen-activated protein kinase
- DISC:
-
death-inducing signaling complex
- PDBu:
-
phorbol-12,13-dibutyrate
- PARP:
-
poly(ADP-ribose)polymerase
- cFLIP:
-
cellular FADD-like interleukin 1-converting enzyme-inhibitory protein
- IAPs:
-
inhibitor-of-apoptosis proteins
- Z-VAD:
-
inhibitor-of-apoptosis proteins
- Z-VAD-FMK:
-
benzyloxycarbonyl-Val-Ala-Asp-(OMe) fluoromethyl ketone
- DiOC6(3):
-
3,3′-dihexyloxacarbocyanine iodide
- CHX:
-
cycloheximide; ψm, membrane potential
References
Thompson CB . 1995 Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456–1462
Steller H . 1995 Mechanisms and genes of cellular suicide. Science 267: 1445–1449
Yeh WC, Hakem R, Woo M and Mak TW . 1999 Gene targeting in the analysis of mammalian apoptosis and TNF receptor superfamily signaling. Immunol. Rev. 169: 283–302
Ashkenazi A and Dixit VM . 1999 Apoptosis control by death and decoy receptors. Curr. Opin. Cell. Biol. 11: 255–260
Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR and Fanger NA . 1999 Monocyte-mediated tumoricidal activity via the tumor necrosis factor- related cytokine, TRAIL. J. Exp. Med. 189: 1343–1354
Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K and Yagita H . 1999 Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J. Immunol. 162: 2639–2647
Martinez-Lorenzo MJ, Alava MA, Gamen S, Kim KJ, Chuntharapai A, Pineiro A, Naval J and Anel A . 1998 Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur. J. Immunol. 28: 2714–2725
Phillips TA, Ni J, Pan G, Ruben SM, Wei YF, Pace JL and Hunt JS . 1999 TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. J. Immunol. 162: 6053–6059
Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M, Yao X, Puck JM, Straus SE and Lenardo MJ . 1999 Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98: 47–58
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C and Smith CA . 1995 Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673–682
Pitti RM, Masters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A . 1996 Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271: 12687–12690
Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM . 1997 The receptor for the cytotoxic ligand TRAIL. Science 276: 111–113
Pan G, Ni J, Wei YF, Yu G, Gentz R and Dixit VM . 1997 An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815–818
Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A . 1997 Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818–821
Walczak H, Degli EM, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG and Rauch CT . 1997 TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16: 5386–5397
Mongkolsapaya J, Cowper AE, Xu XN, Morris G, McMichael AJ, Bell JI and Screaton GR . 1998 Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J. Immunol. 160: 3–6
Degli EM, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG and Smith CA . 1997 Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186: 1165–1170
Degli EM, Dougall WC, Smolak PJ, Waugh JY, Smith CA and Goodwin RG . 1997 The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7: 813–820
Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P and Ashkenazi A . 1997 A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7: 1003–1006
Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N and Tschopp J . 1997 Characterization of two receptors for TRAIL. FEBS Lett. 416: 329–334
Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J and Hood L . 1997 Death receptor 5, a new member of the TNFR family, and DR4 induce FADD- dependent apoptosis and activate the NF-kappaB pathway. Immunity 7: 821–830
Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N and Tschopp J . 1997 TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7: 831–836
Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD and Ashkenazi A . 1996 Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol. 6: 750–752
Zhang J, Cado D, Chen A, Kabra NH and Winoto A . 1998 Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 392: 296–300
Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El DW, Lowe SW, Goeddel DV and Mak TW . 1998 FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279: 1954–1958
Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J and Tschopp J . 2000 TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell. Biol. 2: 241–243
Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A . 2000 Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611–620
Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH and Walczak H . 2000 FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599–609
Mariani SM, Matiba B, Armandola EA and Krammer PH . 1997 Interleukin 1 beta-converting enzyme related proteases/Caspase are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J. Cell. Biol. 137: 221–229
Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin MZ . 1998 Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161: 2833–2840
MacFarlane M, Merrison W, Dinsdale D and Cohen GM . 2000 Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis. J. Cell. Biol. 148: 1239–1254
Kroemer G, Zamzami N and Susin SA . 1997 Mitochondrial control of apoptosis. Immunol. Today 18: 44–51
Petit PX, Susin SA, Zamzami N, Mignotte B and Kroemer G . 1996 Mitochondria and programmed cell death: back to the future. FEBS Lett. 396: 7–13
Liu X, Kim CN, Yang J, Jemmerson R and Wang X . 1996 Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86: 147–157
Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X . 1997 Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129–1132
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X . 1997 Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479–489
Zou H, Henzel WJ, Liu X, Lutschg A and Wang X . 1997 Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90: 405–413
Srinivasula SM, Ahmad M, Fernandes AT and Alnemri ES . 1998 Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell 1: 949–957
Bossy WE, Newmeyer DD and Green DR . 1998 Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD- specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J. 17: 37–49
Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH and Peter ME . 1998 Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17: 1675–1687
Keogh SA, Walczak H, Bouchier-Hayes L and Martin SJ . 2000 Failure of bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Lett. 471: 93–98
Walczak H, Bouchon A, Stahl H and Krammer PH . 2000 Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res. 60: 3051–3057
Rodriguez-Tarduchy G and A L-R . 1989 Phorbol esters inhibit apoptosis in IL-2-dependent T lymphoctes. Biochem. Biophys. Res. Commun. 164: 1069–1075
Forbes IJ, Zalewski PD, Giannakis C and Cowled PA . 1992 Induction of apoptosis in chronic lymphocytic leukemia cells and its prevention by phorbol ester. Exp. Cell. Res. 198: 367–372
Illera VA, Perandones CE, Stunz LL, Mower DJ and Ashman RF . 1993 Apoptosis in splenic B lymphocytes. Regulation by protein kinase C and IL-4. J. Immunol. 151: 2965–2973
Ruiz-Ruiz M, Izquierdo M, de MG and Lopez RA . 1997 Activation of protein kinase C attenuates early signals in Fas-mediated apoptosis. Eur. J. Immunol. 27: 1442–1450
Su X, Zhou T, Wang Z, Yang P, Jope RS and Mountz JD . 1995 Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fasmediated apoptosis. Immunity 2: 353–362
Ni R, Tomita Y, Matsuda K, Ichihara A, Ishimura K, Ogasawara J and Nagata S . 1994 Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp. Cell. Res. 215: 332–337
Copeland KF, Haaksma AG, Goudsmit J, Krammer PH and Heeney JL . 1994 Inhibition of apoptosis in T cells expressing human T cell leukemia virus type I Tax. Aids Res. Hum. Retroviruses 10: 1259–1268
Leevers SJ and Marshall CJ . 1992 Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein. EMBO J. 11: 569–574
Marais R, Light Y, Mason C, Paterson H, Olson MF and Marshall CJ . 1998 Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 280: 109–112
Whitehurst CE, Boulton TG, Cobb MH and Geppert TD . 1992 Extracellular signal-regulated kinases in T cells. Anti-CD3 and 4 beta-phorbol 12-myristate 13-acetate-induced phosphorylation and activation. J. Immunol. 148: 3230–3237
Holmstrom TH, Chow SC, Elo I, Coffey ET, Orrenius S, Sistonen L and Eriksson JE . 1998 Suppression of Fas/APO-1-mediated apoptosis by mitogen-activated kinase signaling. J. Immunol. 160: 2626–2636
Yeh JH, Hsu SC, Han SH and Lai MZ . 1998 Mitogen-activated protein kinase kinase antagonized fas-associated death domain protein-mediated apoptosis by induced FLICE-inhibitory protein expression. J. Exp. Med. 188: 1795–1802
Ruiz-Ruiz C, Robledo G, Font J, Izquierdo M and Lopez-Rivas A . 1999 Protein kinase C inhibits CD95 (Fas/APO-1)-mediated apoptosis by at least two different mechanisms in Jurkat T cells. J. Immunol. 163: 4737–4746
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH . 1999 Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo. Nat. Med. 5: 157–163
Cohen GM . 1997 Caspases: the executioners of apoptosis. Biochem. J. 326: 1–16
Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG . 1993 Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53: 3976–3985
Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME . 1995 Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14: 5579–5588
Boldin MP, Goncharov TM, Goltsev YV and Wallach D . 1996 Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85: 803–815
Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH and Peter ME . 1997 FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16: 2794–2804
Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH and Peter ME . 1999 Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem. 274: 22532–22538
Klas C, Debatin KM, Jonker RR and Krammer PH . 1993 Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5: 625–630
Fulda S, Meyer E and Debatin KM . 2000 Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res. 60: 3947–3956
Wajant H, Haas E, Schwenzer R, Muhlenbeck F, Kreuz S, Schubert G, Grell M, Smith C and Scheurich P . 2000 Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated Death Domain protein (FADD). J. Biol. Chem. 275: 24357–24366
Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR and Cohen GM . 1999 Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem. 274: 5053–5060
Yamada H, Tada-Oikawa S, Uchida A and Kawanishi S . 1999 TRAIL causes cleavage of Bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB Cells. Biochem. Biophys. Res. Commun. 265: 130–133
Zou H, Li Y, Liu X and Wang X . 1999 An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274: 11549–11556
Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR . 1995 PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270: 27489–27494
Tartaglia LA and Goeddel DV . 1992 Two TNF receptors. Immunol. Today 13: 151–153
Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T and Nagata S . 1993 Lethal effect of the anti-Fas antibody in mice. Nature 364: 806–809
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH . 1999 Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104: 155–162
Griffith TS and Lynch DH . 1998 TRAIL: a molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. 10: 559–563
Rieger J, Naumann U, Glaser T, Ashkenazi A and Weller M . 1998 APO2 ligand: a novel lethal weapon against malignant glioma?. FEBS Lett. 427: 124–128
Kennedy NJ and Budd RC . 1998 Phosphorylation of FADD/MORT1 and Fas by kinases that associate with the membrane-proximal cytoplasmic domain of Fas. J. Immunol. 160: 4881–4888
Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME . 1995 Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326–1331
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE and Tschopp J . 1997 Inhibition of death receptor signals by cellular FLIP. Nature 388: 190–195
Zhang XD, Franco A, Myers K, Gray C, Nguyen T and Hersey P . 1999 Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 59: 2747–2753
Holmstrom TH, Tran SE, Johnson VL, Ahn NG, Chow SC and Eriksson JE . 1999 Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol. Cell. Biol. 19: 5991–6002
Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ and Der CJ . 1998 Increasing complexity of Ras signaling. Oncogene 17: 1395–1413
Sivaraman VS, Wang H, Nuovo GJ and Malbon CC . 1997 Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99: 1478–1483
Majewski M, Nieborowska-Skorska M, Salomoni P, Slupianek A, Reiss K, Trotta R, Calabretta B and Skorski T . 1999 Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. 59: 2815–2819
Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC . 1998 Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318–1321
Li W, Zhang J, Flechner L, Hyun T, Yam A, Franke TF and Pierce JH . 1999 Protein kinase C-alpha overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal. Oncogene 18: 6564–6572
Gong J, Traganos F and Darzynkiewicz Z . 1994 A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal. Biochem. 218: 314–319
Vanags DM, Porn-Ares MI, Coppola S, Burgess DH and Orrenius S . 1996 Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J. Biol. Chem. 271: 31075–31085
Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M and McConkey DJ . 1998 Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92: 4220–4229
Wagenknecht B, Glaser T, Naumann U, Kugler S, Isenmann S, Bahr M, Korneluk R, Liston P and Weller M . 1999 Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ. 6: 370–376
Acknowledgements
Gema Robledo is acknowledged for excellent technical assistance. This work was supported by a grant from the Comisión Interministerial de Ciencia y Tecnología (SAF97-0064-C03-01 and SAF2000-0118-C03-01) to A López-Rivas. M. Sarker is recipient of a fellowship from Agencia Española de Cooperación Internacional (AECI).
Author information
Authors and Affiliations
Corresponding author
Additional information
Edited by C Borner
Rights and permissions
About this article
Cite this article
Sarker, M., Ruiz-Ruiz, C. & López-Rivas, A. Activation of protein kinase C inhibits TRAIL-induced caspases activation, mitochondrial events and apoptosis in a human leukemic T cell line. Cell Death Differ 8, 172–181 (2001). https://doi.org/10.1038/sj.cdd.4400791
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4400791
Keywords
This article is cited by
-
Screening study of cancer-related cellular signals from microbial natural products
The Journal of Antibiotics (2021)
-
TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5
Journal of Molecular Medicine (2010)
-
Inhibition of novel protein kinase Cɛ augments TRAIL-induced cell death in A549 lung cancer cells
Pathology & Oncology Research (2007)
-
The mitogen-activated protein kinase pathway can inhibit TRAIL-induced apoptosis by prohibiting association of truncated Bid with mitochondria
Cell Death & Differentiation (2006)
-
Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines
Oncogene (2005)